A
AVXT
vs
S&P 500
S&P 500
Over the past 12 months, AVXT has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
AVXT vs S&P 500
Performance Gap
AVXT vs S&P 500
Performance By Year
AVXT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AVAX Technologies Inc
Glance View
AVAX Technologies, Inc. is an immuno-oncology company, which engages in the provision of development and commercialization of vaccine therapies and technologies for the treatment of cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 29 full-time employees. The firm is focused on developing and commercializing its Autologous Cell (AC) Vaccine Technology Platform for the treatment of cancer. The AC Vaccine is a platform technology, which allows a patient's immune system to recognize its own cancer cells as foreign through the process of haptenization, cell processing and regimen of administration. The firm has approximately two vaccines that have completed Phase II clinical trials, both designated with Orphan Drug Status. MVAX is a post-surgical autologous cell vaccine for melanoma, which was approved to enter a Phase III-REGISTRATION trial for the treatment of Stage IV melanoma patients with measurable metastasis. OVAX is the Company's post-surgical autologous cell vaccine for Stage III and IV ovarian cancer. The OVAX trial is a Phase I/II trial that has completed enrollment and is in the process of gathering follow-up data on all patients.
